Document is current

Article History

Accepted: 8 August 2022

First Online: 5 September 2022

Declarations

:

: The CGP study was funded the Melbourne Genomics Health Alliance. No funding was received for performing this analysis. Sophie O’Haire was supported by an Australian Government Research Training Program (RTP) Fee-Offset Scholarship through The University of Melbourne.

: SOH, KD, FF, CG, SJL, SF and JD declare no potential conflicts of interest. MIJ receives unrestricted research funding to the University of Melbourne from Illumina. BT reports grants and personal fees from Amgen, grants and personal fees from Astra Zeneca, grants from Astellas, grants and personal fees from BMS, grants and personal fees from Janssen, grants and personal fees from Pfizer, grants and personal fees from MSD, grants and personal fees from Ipsen, personal fees from IQVIA, personal fees from Sanofi, personal fees from Tolmar, personal fees from Novartis, grants and personal fees from Bayer, personal fees from Roche, outside the submitted work.

: The CGP study was approved by Melbourne Health HREC (approval no. HREC/13/MH/326) and approval with waiver of consent granted for de-identified clinical data collection of the No CGP cohort.

: Informed consent was obtained for all participants in the CGP cohort. The requirement for consent was waived for the collection and use of de-identified health outcomes data for the No CGP cohort.

: Not applicable.

: The dataset analysed during the current study is available from the corresponding author on reasonable request.

: Conceptualisation (SOH, KD, FF), Methodology (SOH, KD, FF), Formal Analysis (SOH, KD, FF), Investigation (SOH, BT, SL, KS, SF, JD), Writing—Original Draft (SOH, KD, FF), Writing—Review & Editing (SOH, KD, FF, BT, SL, CG, KS, SF, JD, MIJ), Visualisation (SOH, FF), Supervision (CG, SF, JD, MIJ), Funding Acquisition (CG, SF, JD, MIJ).